Linsitinib is an oral small molecule that inhibits the activity of insulin-like growth factor-1 receptor (IGF-1R). It is believed that inhibition of IGF-1R may help reduce orbital inflammation and ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...

Reduction seen in risk for readmission, wound dehiscence, and hematoma, but no significant differences seen in rates of infection, bleeding ...

Reductions seen in median Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome score, Patient Assessment of Gastrointestinal Symptom Severity Index ...

Four-month regimen recommended for drug-susceptible TB and six-month regimen recommended for drug-resistant TB ...